Reich Kristian 4
4 · MoonLake Immunotherapeutics · Filed Jul 20, 2026
Research Summary
AI-generated summary of this filing
MoonLake (MLTX) CSO Kristian Reich Sells 16,105 Shares
What Happened Kristian Reich, Chief Scientific Officer of MoonLake Immunotherapeutics (MLTX), disposed of 16,105 ordinary shares on July 15, 2026. The weighted-average sale price was $20.01 per share for total proceeds of approximately $322,261. The filing lists the transaction code "S" (sale), indicating an open-market or private sale.
Key Details
- Transaction date: July 15, 2026. Weighted-average price: $20.01; total proceeds: ~$322,261.
- Price range: shares were sold in multiple transactions at prices from $20.00 to $20.04 (per filing footnote).
- Shares owned after the transaction: not specified in the provided filing excerpt.
- Footnotes of note:
- F1: Transaction executed pursuant to a Rule 10b5-1 trading plan adopted March 10, 2026.
- F2: Reported price is a weighted average; detailed per-price share counts available upon SEC staff request.
- F3: Identifies JeruCON Beratungsgesellschaft mbH as an entity whose ordinary shares Dr. Reich may be deemed to beneficially own indirectly.
- Filing timeliness: Form 4 filed July 20, 2026 for a July 15 transaction — this appears to be outside the typical two-business-day reporting window.
Context Because the sale was executed under a Rule 10b5-1 plan (adopted March 10, 2026), it likely reflects a prearranged trading schedule rather than an ad hoc decision; such sales are often routine and should not be interpreted alone as a signal about management’s view of the company.
Insider Transaction Report
- Sale
Class A ordinary shares, par value $0.0001 per share
[F1][F2][F3]2026-07-15$20.01/sh−16,105$322,261→ 2,808,446 total(indirect: See footnote.)
- 35,389
Class A ordinary shares, par value $0.0001 per share
Footnotes (3)
- [F1]This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 10, 2026.
- [F2]The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.04. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- [F3]Represents the ordinary shares of the Issuer owned by JeruCON Beratungsgesellschaft mbH. Dr. Reich directly (whether through ownership or position) or indirectly through one or more intermediaries, may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the ordinary shares owned by JeruCON Beratungsgesellschaft mbH.